Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).
Hirotoshi SakaguchiKatsustugu UmedaItaru KatoKimiyoshi SakaguchiHidefumi HiramatsuHiroyuki IshidaHiromasa YabeHiroaki GotoYuta KawaharaYuka Iijima YamashitaMasashi SanadaTakao DeguchiYoshiyuki TakahashiAkiko SaitoHisashi NomaKeizo HoribeTakashi TagaSouichi Adachinull nullPublished in: BMJ open (2023)
jRCTs041210154.
Keyphrases
- acute lymphoblastic leukemia
- study protocol
- cell therapy
- randomized controlled trial
- double blind
- liver failure
- single cell
- acute myeloid leukemia
- respiratory failure
- clinical trial
- diffuse large b cell lymphoma
- open label
- multiple myeloma
- placebo controlled
- stem cells
- hodgkin lymphoma
- aortic dissection
- drug induced
- mesenchymal stem cells
- mechanical ventilation